Teva's CGRP Inhibitor Fails In Chronic Cluster Headaches, Continues In Episodic
Executive Summary
Unlike the migraine space, there is only one competitor for Teva's CGRP inhibitor in cluster headaches, but that opportunity narrowed with fremanezumab's failure in chronic cluster headaches, though a trial in episodic cluster headaches is ongoing.
You may also be interested in...
Keeping Track Of Breakthrough Therapy Designations: Depression, Headaches, Hepatitis
The latest developments in one of the US FDA's favorite pathways.
Migraine Market Gets Competitive With Second, Third CGRP Inhibitor Launches
CGRP inhibitors were a hot topic during third quarter earnings calls, with Amgen and Teva talking about reimbursement progress, while Lilly marked progress for its add-on treatment, Allergan calmed fears about Botox's migraine sales, and Alder said its intravenous drug is on track.
14 Approvals To Look Out For In Q3
As many as 14 new products are up for US approval in the third quarter, research by Informa Pharma's Biomedtracker shows. Scrip takes a look at the candidates and their chances of reaching the market.